A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation
暂无分享,去创建一个
M. Cohen-Wolkowiez | D. Gonzalez | C. Melloni | K. Zimmerman | J. Ericson | K. Hill | Huali Wu | J. Guptill
[1] F. Huang,et al. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation , 2016, American journal of therapeutics.
[2] Lawrence X. Yu,et al. Erratum to: A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion , 2015, The AAPS Journal.
[3] Asif Khan,et al. Fungal Infections in Renal Transplant Patients , 2015, Journal of clinical medicine research.
[4] R Lionberger,et al. Novel bioequivalence approach for narrow therapeutic index drugs , 2015, Clinical pharmacology and therapeutics.
[5] P. Bárány,et al. Systematic conversion to generic tacrolimus in stable kidney transplant recipients , 2014, Clinical kidney journal.
[6] J. Azzi,et al. Calcineurin Inhibitors: 40 Years Later, Can’t Live Without … , 2013, The Journal of Immunology.
[7] J. Cortelli,et al. Gingival Overgrowth in Renal Transplant Subjects: A 44-Month Follow-Up Study , 2013, Transplantation.
[8] S. Kulkarni,et al. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[9] A. Johnston,et al. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation , 2013, European journal of hospital pharmacy. Science and practice.
[10] G. Russ,et al. A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients , 2013, Transplantation.
[11] S. Mulgaonkar,et al. Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] R. Lee,et al. Current trends in immunosuppressive therapies for renal transplant recipients. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[13] David W. Johnson,et al. Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[14] M. Shakeri,et al. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation. , 2012, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
[15] J. D. de Fijter,et al. Randomized Trial Comparing Late Concentration-Controlled Calcineurin Inhibitor or Mycophenolate Mofetil Withdrawal , 2012, Transplantation.
[16] M. Christiaans,et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[17] T. Keough-Ryan,et al. Generic Immunosuppression in Solid Organ Transplantation: A Canadian Perspective , 2012, Transplantation.
[18] B. Banas,et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[19] R. Alloway,et al. Immunosuppression, Generic Drugs and the FDA , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[20] K. Huh,et al. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. , 2012, Transplantation proceedings.
[21] Y. S. Kim,et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. , 2012, Transplantation proceedings.
[22] E. Tichy,et al. A Multicenter Experience With Generic Tacrolimus Conversion , 2011, Transplantation.
[23] A. Humar,et al. The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] S. Mulgaonkar,et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. , 2011, Kidney international.
[25] Thomas Becker,et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.
[26] S. Hatami,et al. Gingival enlargement and its risk factors in kidney transplant patients receiving cyclosporine A. , 2010, Iranian journal of kidney diseases.
[27] J. Campistol,et al. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[28] J. Joh,et al. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living‐donor renal transplantation: 5‐year follow‐up , 2010, Transplant international : official journal of the European Society for Organ Transplantation.
[29] K. Chau,et al. Long‐term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis , 2009, Nephrology.
[30] V. Meas-Yedid,et al. Interstitial Fibrosis Quantification in Renal Transplant Recipients Randomized to Continue Cyclosporine or Convert to Sirolimus , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] Lawrence X. Yu,et al. Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration , 2009, The Annals of pharmacotherapy.
[32] C. O’Seaghdha,et al. Higher tacrolimus trough levels on days 2–5 post‐renal transplant are associated with reduced rates of acute rejection , 2009, Clinical transplantation.
[33] B. Krämer. Tacrolimus prolonged release in kidney transplantation , 2009, Expert review of clinical immunology.
[34] Minnie Sarwal,et al. Calcineurin inhibitor nephrotoxicity. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[35] F. Schena,et al. Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.
[36] A. Gaber,et al. Comparison of Sirolimus Plus Tacrolimus Versus Sirolimus Plus Cyclosporine in High-Risk Renal Allograft Recipients: Results From an Open-Label, Randomized Trial , 2008, Transplantation.
[37] J. A. Al Wakeel,et al. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral. , 2008, Transplantation proceedings.
[38] A. Henning,et al. Optimizing Tacrolimus Therapy in the Maintenance of Renal Allografts: 12-Month Results , 2008, Transplantation.
[39] C. Ronco,et al. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] A. Shokeir,et al. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience. , 2008, Iranian journal of kidney diseases.
[41] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[42] R. Viebahn,et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[43] P. Kuo,et al. One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] Edward Cole,et al. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[45] T. Larson,et al. Comparison of Low Versus High Tacrolimus Levels in Kidney Transplantation: Assessment of Efficacy by Protocol Biopsies , 2007, Transplantation.
[46] Kim-Ming Wong,et al. Paired kidney analysis of tacrolimus and cyclosporine microemulsion‐based therapy in Chinese cadaveric renal transplant recipients , 2006, Transplant international : official journal of the European Society for Organ Transplantation.
[47] A. Barbari,et al. Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study. , 2006, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
[48] D. Abramowicz,et al. Tacrolimus Combined with Two Different Dosages of Sirolimus in Kidney Transplantation: Results of a Multicenter Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[49] J. Rogers,et al. Does Bioequivalence Between Modified Cyclosporine Formulations Translate into Equal Outcomes? , 2005, Transplantation.
[50] G. Russ,et al. Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function , 2005, Transplantation.
[51] M. Ghoneim,et al. Comparison of Sirolimus with Low‐Dose Tacrolimus Versus Sirolimus‐based Calcineurin Inhibitor‐Free Regimen in Live Donor Renal Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[52] T. Waid. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure , 2005, Clinical transplantation.
[53] F. Schena,et al. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. , 2005, Transplantation proceedings.
[54] J. Till,et al. Inflation Targets Versus International Monetary Integration - a Canadian Perspective , 2002, SSRN Electronic Journal.
[55] D. Kuypers. Benefit-Risk Assessment of Sirolimus in Renal Transplantation , 2005, Drug safety.
[56] F. Schena,et al. Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[57] J. Joh,et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. , 2004, Transplantation proceedings.
[58] P. Friend,et al. Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies * , 2004, Clinical transplantation.
[59] T. Larson,et al. WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1 , 2004, Transplantation.
[60] B. Maes,et al. Clinical Efficacy and Toxicity Profile of Tacrolimus and Mycophenolic Acid in Relation to Combined Long‐term Pharmacokinetics in de Novo Renal Allograft Recipients , 2004, Clinical pharmacology and therapeutics.
[61] L. Gaber,et al. Observations regarding the use of sirolimus and tacrolimus in high‐risk cadaveric renal transplantation , 2004, Clinical transplantation.
[62] C. Dudley,et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients , 2003, Transplantation.
[63] P. Keown,et al. A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A , 2003 .
[64] G. Russ,et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. , 2003, Transplantation proceedings.
[65] P. Keown,et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001. , 2003, Clinical therapeutics.
[66] B. Krämer,et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. , 2002, Transplantation proceedings.
[67] R. Margreiter. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study , 2002, The Lancet.
[68] K. Salmela,et al. Early cyclosporine concentration as predictor of graft survival in cadaveric renal transplantation. , 2001, Transplantation proceedings.
[69] B. Kaplan,et al. RAD IN DE NOVO RENAL TRANSPLANTATION: COMPARISON OF THREE DOSES ON THE INCIDENCE AND SEVERITY OF ACUTE REJECTION 1 , 2001, Transplantation.
[70] H. Sperschneider. A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. , 2001, Transplantation proceedings.
[71] A. Macdonald. A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS , 2001, Transplantation.
[72] J. Podbielski,et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity , 2000, Clinical transplantation.
[73] B. Julian,et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. , 1999, Transplantation.
[74] G. Tydén,et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. , 1999, British journal of clinical pharmacology.
[75] M. Choc. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune® , 1997, International journal of dermatology.
[76] D Talbot,et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. , 1997, Transplantation.
[77] Joshua Miller,et al. A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .
[78] J. Pirsch,et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. , 1997, Transplantation.
[79] P. Reinke,et al. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. , 1996, International journal of clinical pharmacology and therapeutics.
[80] A. Matas,et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. , 1996, Transplantation.
[81] R. Kershner,et al. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.
[82] C. Ponticelli,et al. Randomized study with cyclosporine in kidney transplantation: 10-year follow-up. , 1996, Journal of the American Society of Nephrology : JASN.
[83] M. Christiaans,et al. FK 506 versus cyclosporin in the prevention of renal allograft rejection — European pilot study: six-week results , 1995 .
[84] J. Pirsch,et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. , 1994, The New England journal of medicine.
[85] B. Kahan,et al. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.
[86] D. Freeman. Pharmacology and pharmacokinetics of cyclosporine. , 1991, Clinical biochemistry.
[87] D. Holt,et al. Value of cyclosporine measurements in renal transplant recipients immunosuppressed with triple therapy. , 1990, Transplantation proceedings.
[88] B. Kasiske,et al. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. , 1988, Transplantation.
[89] J. Najarian,et al. Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin-azathioprine. , 1986, Transplantation proceedings.
[90] A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. , 1986, The New England journal of medicine.
[91] H. Sharma,et al. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. , 1985, American journal of surgery.